Serum urate and probability of dopaminergic deficit in early “Parkinson's disease”
- 29 April 2011
- journal article
- research article
- Published by Wiley in Movement Disorders
- Vol. 26 (10) , 1864-1868
Abstract
The objective of this study was to investigate whether higher levels of urate, an antioxidant linked to a lower likelihood of developing Parkinson's disease, is also a predictor of having a dopamine transporter brain scan without evidence of dopaminergic deficit. In a cross‐sectional study of 797 mildly affected, untreated parkinsonian subjects diagnosed with early Parkinson's disease in the Parkinson Research Examination of CEP‐1347 Trial, we investigated the relationship at baseline between serum urate and striatal dopamine transporter density, determined by single‐photon emission computed tomography of iodine‐123‐labeled 2‐β‐carboxymethoxy‐3‐β‐(4‐iodophenyl)tropane uptake. A scan without evidence of dopaminergic deficit was defined as lowest putamen iodine‐123‐labeled 2‐β‐carboxymethoxy‐3‐β‐(4‐iodophenyl)tropane > 80% age‐expected putamen dopamine transporter density. The odds of having a scan without evidence of dopaminergic deficit rose across increasing quintiles of urate level, with an age‐ and sex‐adjusted odds ratio of 3.2 comparing the highest to the lowest urate quintile (95% confidence interval, 1.5–7.2; P for trend = .0003), and remained significant after adjusting for potential confounding factors. The association was significant in men but not women, regardless of whether common or sex‐specific quintiles of urate were used. Higher levels of urate were associated with a greater likelihood of a scan without evidence of dopaminergic deficit among subjects with early untreated parkinsonism in the Parkinson Research Examination of CEP‐1347 Trial. The findings support the diagnostic utility of urate in combination with other determinants. © 2011 Movement Disorder SocietyKeywords
This publication has 24 references indexed in Scilit:
- Variation in the Uric Acid Transporter Gene SLC2A9 and Its Association with AAO of Parkinson’s DiseaseJournal of Molecular Neuroscience, 2010
- Mitochondria take center stage in aging and neurodegenerationAnnals of Neurology, 2005
- Survival in Parkinson diseaseNeurology, 2005
- Levodopa and the Progression of Parkinson's DiseaseNew England Journal of Medicine, 2004
- (123I) β-CIT and Single-Photon Emission Computed Tomographic Imaging vs Clinical Evaluation in Parkinsonian SyndromeArchives of Neurology, 2004
- Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET studyAnnals of Neurology, 2003
- [ 123 I]β-CIT SPECT imaging assessment of the rate of Parkinson’s disease progressionNeurology, 2001
- Observations on Serum Uric Acid Levels and the Risk of Idiopathic Parkinson's DiseaseAmerican Journal of Epidemiology, 1996
- Parkinson's disease: A chronic, low-grade antioxidant deficiency?Medical Hypotheses, 1994
- Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis.Proceedings of the National Academy of Sciences of the United States of America, 1981